Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis
Background There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different com...
Gespeichert in:
Veröffentlicht in: | Digestive diseases and sciences 2020-12, Vol.65 (12), p.3719-3725 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3725 |
---|---|
container_issue | 12 |
container_start_page | 3719 |
container_title | Digestive diseases and sciences |
container_volume | 65 |
creator | Le, Long Kullar, Ravina Saleh, Hussein M. Saab, Sammy |
description | Background
There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different combinations of NITs to detect advanced fibrosis in NAFLD.
Methods
We stratified NITs into first and second tiers and compared two different strategies of combining NITs to screen for advanced fibrosis in patients with NAFLD. One strategy was using NITs in parallel, and the other was using NITs sequentially. Within both of these strategies, there were two ways of interpreting the overall results. The first way was called “the AND rule,” where a positive result required both individual test results to be positive. The second way was called “the OR rule,” where a positive result required only one individual test to be positive. Accuracy of NITs was obtained from the literature search. Combined accuracy and likelihood ratio (LR) were calculated.
Results
Combination testing with parallel and sequential order testing under the AND Rule resulted in overall higher specificity and LR+ then using the NITs alone. Specificity ranged from 0.91 to 0.99, and LR+ from 9.3 to 68.6. The subsequent use of MRE was associated with LR+ between 36 and 69. Sensitivity was higher with parallel and sequential order testing under the OR Rule. LR+ ranged from 1.4 to 7.5, and sensitivity from 0.82 to 0.98.
Conclusion
Screening for advanced fibrosis should be performed sequentially, with positive results confirmed by additional testing. Specificity and LR+ were highest when MRE was employed as the confirmatory test. |
doi_str_mv | 10.1007/s10620-020-06382-4 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2424448005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712935137</galeid><sourcerecordid>A712935137</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-33c2d534fb27dcc1ba94bbaf4a3efaf7744d97d109982af4ef58f0efaaa3f6f53</originalsourceid><addsrcrecordid>eNp9kdtKAzEQhoMotlZfwAspeOPN1pw22b0RiniCooL1OmSzkxrZbmqyFXx7s9QDikgYEma-f5jJj9AhwROCsTyNBAuKM9yHYAXN-BYaklyyjOai2EZDTER6EyIGaC_GZ4xxKYnYRQNGhSR5wYfo7D6AhRCgHt_61rWvOrpXGM8hdq5djK0PfV43xj_5xpnxQwe680-w0p3rXNxHO1Y3EQ4-7hF6vLyYn19ns7urm_PpLDOc0y5jzNA6Z9xWVNbGkEqXvKq05ZqB1VZKzutS1gSXZUFTGmxeWJxKWjMrbM5G6GTTdxX8yzoNp5YuGmga3YJfR0U55ZwXGPfo8S_02a9DWqGnJOG5FLL4pha6AeVa67ugTd9UTSWhJcsJk4ma_EGlU8PSGd-CdSn_Q0A3AhN8jOlr1Sq4pQ5vimDVm6Y2pincR2-a4kl09DHxulpC_SX5dCkBbAPEVGoXEL5X-qftO9cSoL8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471457678</pqid></control><display><type>article</type><title>Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Le, Long ; Kullar, Ravina ; Saleh, Hussein M. ; Saab, Sammy</creator><creatorcontrib>Le, Long ; Kullar, Ravina ; Saleh, Hussein M. ; Saab, Sammy</creatorcontrib><description>Background
There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different combinations of NITs to detect advanced fibrosis in NAFLD.
Methods
We stratified NITs into first and second tiers and compared two different strategies of combining NITs to screen for advanced fibrosis in patients with NAFLD. One strategy was using NITs in parallel, and the other was using NITs sequentially. Within both of these strategies, there were two ways of interpreting the overall results. The first way was called “the AND rule,” where a positive result required both individual test results to be positive. The second way was called “the OR rule,” where a positive result required only one individual test to be positive. Accuracy of NITs was obtained from the literature search. Combined accuracy and likelihood ratio (LR) were calculated.
Results
Combination testing with parallel and sequential order testing under the AND Rule resulted in overall higher specificity and LR+ then using the NITs alone. Specificity ranged from 0.91 to 0.99, and LR+ from 9.3 to 68.6. The subsequent use of MRE was associated with LR+ between 36 and 69. Sensitivity was higher with parallel and sequential order testing under the OR Rule. LR+ ranged from 1.4 to 7.5, and sensitivity from 0.82 to 0.98.
Conclusion
Screening for advanced fibrosis should be performed sequentially, with positive results confirmed by additional testing. Specificity and LR+ were highest when MRE was employed as the confirmatory test.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-020-06382-4</identifier><identifier>PMID: 32671584</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Accuracy ; Biochemistry ; Biopsy ; Biopsy - methods ; Clinical Decision Rules ; Comparative analysis ; Elasticity Imaging Techniques - methods ; Gastroenterology ; Hepatology ; Humans ; Laboratories ; Liver ; Liver - diagnostic imaging ; Liver - pathology ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - etiology ; Liver diseases ; Mass Screening - methods ; Medicine ; Medicine & Public Health ; Mortality ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - diagnosis ; Oncology ; Original Article ; Sensitivity and Specificity ; Transplant Surgery</subject><ispartof>Digestive diseases and sciences, 2020-12, Vol.65 (12), p.3719-3725</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-33c2d534fb27dcc1ba94bbaf4a3efaf7744d97d109982af4ef58f0efaaa3f6f53</citedby><cites>FETCH-LOGICAL-c442t-33c2d534fb27dcc1ba94bbaf4a3efaf7744d97d109982af4ef58f0efaaa3f6f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10620-020-06382-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10620-020-06382-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32671584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Le, Long</creatorcontrib><creatorcontrib>Kullar, Ravina</creatorcontrib><creatorcontrib>Saleh, Hussein M.</creatorcontrib><creatorcontrib>Saab, Sammy</creatorcontrib><title>Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background
There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different combinations of NITs to detect advanced fibrosis in NAFLD.
Methods
We stratified NITs into first and second tiers and compared two different strategies of combining NITs to screen for advanced fibrosis in patients with NAFLD. One strategy was using NITs in parallel, and the other was using NITs sequentially. Within both of these strategies, there were two ways of interpreting the overall results. The first way was called “the AND rule,” where a positive result required both individual test results to be positive. The second way was called “the OR rule,” where a positive result required only one individual test to be positive. Accuracy of NITs was obtained from the literature search. Combined accuracy and likelihood ratio (LR) were calculated.
Results
Combination testing with parallel and sequential order testing under the AND Rule resulted in overall higher specificity and LR+ then using the NITs alone. Specificity ranged from 0.91 to 0.99, and LR+ from 9.3 to 68.6. The subsequent use of MRE was associated with LR+ between 36 and 69. Sensitivity was higher with parallel and sequential order testing under the OR Rule. LR+ ranged from 1.4 to 7.5, and sensitivity from 0.82 to 0.98.
Conclusion
Screening for advanced fibrosis should be performed sequentially, with positive results confirmed by additional testing. Specificity and LR+ were highest when MRE was employed as the confirmatory test.</description><subject>Accuracy</subject><subject>Biochemistry</subject><subject>Biopsy</subject><subject>Biopsy - methods</subject><subject>Clinical Decision Rules</subject><subject>Comparative analysis</subject><subject>Elasticity Imaging Techniques - methods</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Liver</subject><subject>Liver - diagnostic imaging</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver diseases</subject><subject>Mass Screening - methods</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - diagnosis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Sensitivity and Specificity</subject><subject>Transplant Surgery</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kdtKAzEQhoMotlZfwAspeOPN1pw22b0RiniCooL1OmSzkxrZbmqyFXx7s9QDikgYEma-f5jJj9AhwROCsTyNBAuKM9yHYAXN-BYaklyyjOai2EZDTER6EyIGaC_GZ4xxKYnYRQNGhSR5wYfo7D6AhRCgHt_61rWvOrpXGM8hdq5djK0PfV43xj_5xpnxQwe680-w0p3rXNxHO1Y3EQ4-7hF6vLyYn19ns7urm_PpLDOc0y5jzNA6Z9xWVNbGkEqXvKq05ZqB1VZKzutS1gSXZUFTGmxeWJxKWjMrbM5G6GTTdxX8yzoNp5YuGmga3YJfR0U55ZwXGPfo8S_02a9DWqGnJOG5FLL4pha6AeVa67ugTd9UTSWhJcsJk4ma_EGlU8PSGd-CdSn_Q0A3AhN8jOlr1Sq4pQ5vimDVm6Y2pincR2-a4kl09DHxulpC_SX5dCkBbAPEVGoXEL5X-qftO9cSoL8</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Le, Long</creator><creator>Kullar, Ravina</creator><creator>Saleh, Hussein M.</creator><creator>Saab, Sammy</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20201201</creationdate><title>Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis</title><author>Le, Long ; Kullar, Ravina ; Saleh, Hussein M. ; Saab, Sammy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-33c2d534fb27dcc1ba94bbaf4a3efaf7744d97d109982af4ef58f0efaaa3f6f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Accuracy</topic><topic>Biochemistry</topic><topic>Biopsy</topic><topic>Biopsy - methods</topic><topic>Clinical Decision Rules</topic><topic>Comparative analysis</topic><topic>Elasticity Imaging Techniques - methods</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Liver</topic><topic>Liver - diagnostic imaging</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver diseases</topic><topic>Mass Screening - methods</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - diagnosis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Sensitivity and Specificity</topic><topic>Transplant Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Le, Long</creatorcontrib><creatorcontrib>Kullar, Ravina</creatorcontrib><creatorcontrib>Saleh, Hussein M.</creatorcontrib><creatorcontrib>Saab, Sammy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Le, Long</au><au>Kullar, Ravina</au><au>Saleh, Hussein M.</au><au>Saab, Sammy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>65</volume><issue>12</issue><spage>3719</spage><epage>3725</epage><pages>3719-3725</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Background
There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different combinations of NITs to detect advanced fibrosis in NAFLD.
Methods
We stratified NITs into first and second tiers and compared two different strategies of combining NITs to screen for advanced fibrosis in patients with NAFLD. One strategy was using NITs in parallel, and the other was using NITs sequentially. Within both of these strategies, there were two ways of interpreting the overall results. The first way was called “the AND rule,” where a positive result required both individual test results to be positive. The second way was called “the OR rule,” where a positive result required only one individual test to be positive. Accuracy of NITs was obtained from the literature search. Combined accuracy and likelihood ratio (LR) were calculated.
Results
Combination testing with parallel and sequential order testing under the AND Rule resulted in overall higher specificity and LR+ then using the NITs alone. Specificity ranged from 0.91 to 0.99, and LR+ from 9.3 to 68.6. The subsequent use of MRE was associated with LR+ between 36 and 69. Sensitivity was higher with parallel and sequential order testing under the OR Rule. LR+ ranged from 1.4 to 7.5, and sensitivity from 0.82 to 0.98.
Conclusion
Screening for advanced fibrosis should be performed sequentially, with positive results confirmed by additional testing. Specificity and LR+ were highest when MRE was employed as the confirmatory test.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32671584</pmid><doi>10.1007/s10620-020-06382-4</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-2116 |
ispartof | Digestive diseases and sciences, 2020-12, Vol.65 (12), p.3719-3725 |
issn | 0163-2116 1573-2568 |
language | eng |
recordid | cdi_proquest_miscellaneous_2424448005 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Accuracy Biochemistry Biopsy Biopsy - methods Clinical Decision Rules Comparative analysis Elasticity Imaging Techniques - methods Gastroenterology Hepatology Humans Laboratories Liver Liver - diagnostic imaging Liver - pathology Liver Cirrhosis - diagnosis Liver Cirrhosis - etiology Liver diseases Mass Screening - methods Medicine Medicine & Public Health Mortality Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - diagnosis Oncology Original Article Sensitivity and Specificity Transplant Surgery |
title | Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A40%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preferred%20Noninvasive%20Testing%20for%20Nonalcoholic%20Steatohepatitis&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Le,%20Long&rft.date=2020-12-01&rft.volume=65&rft.issue=12&rft.spage=3719&rft.epage=3725&rft.pages=3719-3725&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-020-06382-4&rft_dat=%3Cgale_proqu%3EA712935137%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471457678&rft_id=info:pmid/32671584&rft_galeid=A712935137&rfr_iscdi=true |